Efficacy News and Research

RSS

Decision Resources reports increased uptake of TNF-alpha inhibitors for Crohn's disease

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that compared to last year's analysis of U.S. patient-level claims data, TNF-alpha inhibitors are being used more often to treat newly diagnosed patients suffering from Crohn's disease.

9 Dec 2009

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Sangamo BioSciences, Inc. announced today the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for amyotrophic lateral sclerosis (ALS) at a Work in Progress session at the 20th International Symposium on ALS/MND held in Berlin, Germany.

9 Dec 2009

Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML

In a large clinical trial, nilotinib demonstrated greater efficacy over the current gold standard treatment, imatinib, in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase.

9 Dec 2009

Rats exposed to passive smoking become dependent on nicotine, reveals study

Rats passively exposed to tobacco smoke become dependent on nicotine, according to a new study by Dr. Adrie Bruijnzeel and colleagues from the University of Florida in the US. Their findings of how rats' brains respond to exposure to tobacco smoke have implications for the study of the effects of tobacco smoke on the human brain even from passive exposure to other smokers, and for future studies testing new treatments for tobacco addiction. Their work has just been published online in Springer's journal Psychopharmacology.

9 Dec 2009

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

Oxagen Limited, a drug discovery and development company specializing in inflammation, today announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.

9 Dec 2009

CSC's stem cell-derived motor neuron product for SMA receives FDA orphan drug designation

California Stem Cell, Inc. (CSC) and Families of Spinal Muscular Atrophy (FSMA) announced today that the FDA has granted orphan drug designation to MOTORGRAFT™, a stem cell-derived motor neuron product, for the treatment of Spinal Muscular Atrophy (SMA).

9 Dec 2009

Nutrient-rich diet is the best way to stay healthy and reduce risk of chronic diseases

While supplements can help some people meet their nutrition needs, eating a wide variety of nutrient-rich foods is the best way for most people to obtain the nutrients they need to be healthy and reduce their risk of chronic disease, according to a newly updated position paper titled "Nutrient Supplementation" from the American Dietetic Association.

9 Dec 2009

First-quarter fiscal 2010 results announced by Helix BioPharma

Helix BioPharma Corp. today announced financial results for the first quarter ended October 31, 2009.

9 Dec 2009

Mouse model may help identify unknown mutations that make lung cancer cells resistant to therapy

Lung cancer is the leading cause of cancer mortality worldwide and lung adenocarcinoma is the most common type. Many cases of lung adenocarcinoma are attributed to a mutation in a gene for the epidermal growth factor receptor (EGFR).

9 Dec 2009

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin’s lymphoma (NHL) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

9 Dec 2009

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no longer responded to rituximab.

9 Dec 2009

Physicians trust the safety and efficacy of H1N1 vaccine

A recent visit to the pediatric H1N1 vaccine clinic at a major Chicago medical center showed a surprising clientele - most parents bringing their children for vaccination were also medical professionals.

9 Dec 2009

New findings suggest Ginkgo extract can improve cognitive functions

"Ginkgo biloba not only improves declining memory but offers specific benefits for other cognitive functions as well" that's how Dr. Reiner Kaschel, Clinical Neuropsychologist at the University of Osnabrueck, Germany, summarizes the results of a comprehensive new scientific publication.

9 Dec 2009

Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, has completed a Phase 3 clinical trial of Lymphoseek® (NEO3-05) with positive results.

9 Dec 2009

Scientists identify new potential drug for treating acute myeloid leukaemia

EUREKA project E! 3172 NKSTIM has produced a new potential drug to stimulate cancer patients' own 'natural killer' cells to attack and eliminate cancer cells; currently undergoing clinical testing in patients with leukaemia or myeloma.

8 Dec 2009

The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children

The National Fragile X Foundation has awarded a translational research seed grant of $100,000 to Dr. Randi J. Hagerman at the UC Davis M.I.N.D. Institute in California for a study of minocycline in the treatment of children with fragile X syndrome (FXS). Hagerman is an internationally recognized clinician and clinical researcher on FXS, the most common cause of inherited mental impairment.

8 Dec 2009

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Millennium: The Takeda Oncology Company today reported the presentation of results from a double randomized Phase III clinical trial of VELCADE based combinations for the treatment of patients with previously untreated multiple myeloma (MM). The VELCADE based combinations evaluated in the study demonstrated two-year overall survival rates ranging between 81 and 88 percent.

8 Dec 2009

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Sickle cell disease, a condition characterized by deformed and dysfunctional red blood cells, is one of the most common genetic blood disorders affecting millions of people around the world, including more than 70,000 Americans (National Heart, Lung, and Blood Institute.

8 Dec 2009

Erbitux gaining market share of Avastin in Europe

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.

8 Dec 2009

BIOGUARD barrier gauze dressings exhibit high antiviral efficacy against H1N1 virus

An independent lab report demonstrated that BIOGUARD™ barrier gauze dressings exhibit greater than 99.9% inactivation rates against swine flu virus after exposure for 24 hours.

8 Dec 2009

Efficacy News and Research

Decision Resources reports increased uptake of TNF-alpha inhibitors for Crohn's disease

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML

Rats exposed to passive smoking become dependent on nicotine, reveals study

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

CSC's stem cell-derived motor neuron product for SMA receives FDA orphan drug designation

Nutrient-rich diet is the best way to stay healthy and reduce risk of chronic diseases

First-quarter fiscal 2010 results announced by Helix BioPharma

Mouse model may help identify unknown mutations that make lung cancer cells resistant to therapy

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

Physicians trust the safety and efficacy of H1N1 vaccine

New findings suggest Ginkgo extract can improve cognitive functions

Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients

Scientists identify new potential drug for treating acute myeloid leukaemia

The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Erbitux gaining market share of Avastin in Europe

BIOGUARD barrier gauze dressings exhibit high antiviral efficacy against H1N1 virus

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News